Contact:
4008465777
-
About Us
News & Events
-
01-17
Tonghua Dongbao: novel URAT1 inhibitor (THDBH130 Tablets) meets primary endpoint in phase IIa clinical trial
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao"), recently completed a multicenter, ran...
-
12-11
Tonghua Dongbao: Clinical trial application for dual GLP-1/GIP receptor agonist (THDBH120 injection) approved
Recently, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. (“Dongbao Zixing”), a wholly-owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the “Company” or “Tonghua Dongbao”) rec...
-
12-05
Tonghua Dongbao: Liraglutide injection approved for marketing
Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") recently received the Pharmaceutical Product Registration Certificate for liraglutide injection issued by National Medical...
-
11-01
Tonghua Dongbao: Net profit excluding non-recurring gains and losses attributable to shareholders of the parent company up 26.19% YoY in Q3 2023
On the evening of October 30, 2023, Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") released its quarterly report for Q3 2023. In Q3 2023, the Company's revenue was R...
-
10-24
Tonghua Dongbao: BC Combo meets primary endpoint in phase I clinical trial in Germany
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") completed three key phase I clinical trials of BC Combo (THDB0207), a soluble insulin glargine and insulin lispr...
-
10-17
Tonghua Dongbao obtains the Pharmaceutical Product Registration Certificate for empagliflozin tablets
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (the “Company” or “Tonghua Dongbao”) received the Pharmaceutical Product Registration Certificate for empagliflozin tablets issued by the Nationa...